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Abstract
Resident bacterial communities (microbiota) and host antimicrobial peptides
(AMPs) are both essential components of normal host innate immune responses
that limit infection and pathogen induced inflammation. However, their
interdependence has not been investigated in the context of urinary tract infection
(UTI) susceptibility. Here, we explored the interrelationship between the urinary
microbiota and host AMP responses as mechanisms for UTI risk. Using
prospectively collected day of surgery (DOS) urine specimens from female pelvic
floor surgery participants, we report that the relative abundance and/or frequency of
specific urinary microbiota distinguished between participants who did or did not
develop a post-operative UTI. Furthermore, UTI risk significantly correlated with
both specific urinary microbiota and b-defensin AMP levels. Finally, urinary AMP
hydrophobicity and protease activity were greater in participants who developed
UTI, and correlated positively with both UTI risk and pelvic floor symptoms. These
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data demonstrate an interdependency between the urinary microbiota, AMP
responses and symptoms, and identify a potential mechanism for UTI risk.
Assessment of bacterial microbiota and host innate immune AMP responses in
parallel may identify increased risk of UTI in certain populations.
Introduction
Urinary tract infections (UTIs) are the most common type of bacterial infection,
frequently nosocomial infections, and have estimated treatment costs exceeding
$1 billion/year. Some UTI risk factors include female gender, older age, and
having surgery for pelvic organ prolapse (POP) and/or urinary incontinence (UI)
[1–3].
Pelvic floor disorders, including POP and UI, are also common. Approximately
one quarter of women experience a pelvic floor disorder during their lifetime, and
approximately one in ten women undergo POP/UI surgery annually [4, 5].
Despite clinical care strategies designed to eradicate potential pathogens prior to
POP/UI surgery, women who have undergone POP/UI surgery are more likely to
develop a UTI in the early post-operative period, presumably due to urinary tract
instrumentation, compared to males or females undergoing other surgical
procedures [6]. Even with sterile surgical technique, appropriate urinary catheter
insertion methods, quality catheter hygiene and prophylactic antibiotic regimens,
a significant proportion (,20% of urogynecologic patients) experience UTI
within the first 6 weeks after POP/UI surgery and catheter removal [7]. Despite
the clear increased risk of UTI for patients undergoing POP/UI surgery, clinicians
lack scientifically valid methods to identify, and ultimately treat, specific patients
with an increased UTI risk.
Emerging evidence challenges the current paradigm that the bladder is a sterile
microenvironment, and reveals that live bacteria are present in the bladder [8–12],
even in ‘culture-negative’ patients. We recently identified bacteria in the bladders
(urinary microbiota) of continent and incontinent adult females. Using a high-
throughput culture-independent 16S rDNA sequencing approach, we found
compelling evidence that bacteria are often present in urine from ‘culture-
negative’ women who do not have a clinical UTI [13] and used a novel expanded
quantitative urine culture protocol to cultivate many bacterial species that are
often missed by conventional cultivation-dependent approaches [14]. We also
reported DNA-based evidence that certain urinary microbiota characteristics
associate with increased urinary urgency incontinence episodes, but fewer overt
post-instrumentation UTIs [15]. More recently, we determined that women with
or without urgency urinary incontinence exhibit vastly different urinary
microbiomes using both 16S gene sequencing and culture-based methods. We
determined that the urgency urinary incontinence microbiome was composed of
increased Gardnerella and decreased Lactobacillus compared to controls. Several
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genera were more frequently cultured from the urgency urinary incontinence
cohort, as compared to the microbiome of those individuals without urgency
urinary incontinence, with Lactobacillus gasseri identified more robustly detected
in the urgency urinary incontinence cohort and Lactobacillus crispatus more
robustly detected in controls [16]. These data raise the possibility that the urinary
microbiota play a role in maintaining urinary microbial equilibrium, and that
these differences likely contribute to the clinical manifestations of pelvic floor
pathology, including UTI.
Given the discovery and confirmation of a female urinary microbiome, an
understanding of the role of the innate immune system is necessary, as it is a
biologically plausible mechanism to maintain urinary microbial equilibrium.
Antimicrobial peptides (AMPs) are a structurally diverse group of peptides that
are fundamental components of the innate immune system. AMPs contribute to
innate host defense by providing bactericidal or bacteriostatic activity prior to
subsequent innate and adaptive immune responses [17, 18]. Several antimicrobial
proteins and peptides have been detected in the urinary tract from asymptomatic
individuals or from those with active UTI; these include cathelicidin, human b-
defensin-1 (HBD-1), HBD2, cathelicidin, psoriasin, lactoferrin and RNAse7 [19–
25]. Defensins are cationic peptides are classified into a-, b-, and h defensins
based upon their sequence homology and cysteine residues [26]. HBD1 is
constitutively expressed in epithelia, predominantly in the kidney and female
genital tract [21]. HBD2 is induced in response to inflammation or infection and
serves to augment epithelial barriers exposed to bacteria or inflammatory
mediators [27, 28]. Prior work in bladder epithelial systems has demonstrated that
AMP abundance in the epithelial microenvironment is associated with disease
severity or inflammation [29]. In humans with UTI, HBD1 and lactoferrin are
elevated in urine [30, 31], whereas urinary psoriasin was identified as a biomarker
for squamous cell carcinoma of the bladder [32]. A critical role for AMPs in UTI
resistance was identified in b-defensin-1-deficient mice, whose bladders were
more frequently colonized with S. aureus than were the bladders of wild-type mice
[33]. In a separate study, urothelial-derived cathelicidin was shown to confer
protection against uropathogens, as cathelicidin-deficient mice exhibited a more
rapid ascending E. coli infection compared to wild-type mice. It was concluded
that urinary cathelicidin is derived primarily from the urothelium, as cathelicidin
levels did not correlate with urinary leukocyte counts [25]. Collectively, these data
demonstrate the importance of AMPs in the urinary tract, and suggest that AMP
dysfunction may increase UTI risk.
The interdependence of the urinary microbiota and AMPs in the context of
UTI susceptibility has not been investigated. Here, we explored the interrela-
tionship between the urinary microbiota, urinary AMPs and UTI symptom
severity in females undergoing POP/UI surgery. We report that the relative
abundance and/or frequency of certain members of the urinary microbiota in
urines obtained on the day of surgery (DOS) can distinguish between POP/UI
subjects who will or will not develop a post-operative UTI. We also report a
positive correlation between a greater abundance of urinary HBD1 in subjects
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with POP symptoms and reduced risk of post-operative UTI. Finally, we
investigated potential mechanisms for the variable microbiota between cohorts
and determined that AMP activity and hydrophobicity, as well as urinary protease
activity, are significantly more robust in individuals whose DOS urine cultures
were positive for typical uropathogens or in individuals whose cultures became
positive following surgery. Individuals whose DOS cultures were negative and
exhibited no signs of UTI following surgery had minimal AMP activity and
hydrophobicity, as well as urinary protease activity. Thus, the urinary microbiota
and AMP profile have the potential to be used as biomarkers to identify women at
increased risk for post-operative UTI prior to POP/UI surgery. Such identification
of a high-risk group would facilitate interventional clinical trials aimed at
prevention of or improved treatment strategies for UTI.
Results
Clinical Assessment and Patient Demographics
Fifty-four women participated in this study by completing an extensive pre-
operative questionnaire (Table 1 and data not shown) and providing a
catheterized urine specimen (obtained under anesthesia on the day of surgery).
Thirteen participants (24%) had positive DOS urine cultures. The rest (n541,
76%) had negative DOS urine cultures. Of these 54 women, 10 (18%) developed
post-operative urinary symptoms, while 4 (7%) had positive post-operative
cultures. Based on DOS and post-operative cultures, we divided the participants
into 3 cohorts: those that had positive DOS urine cultures (POS, n513, 24%),
those that had negative DOS urine cultures but had positive post-operative urine
cultures (PostI-UTI, n54, 7%) and those that never had a positive urine culture
(negative DOS urine cultures and no positive post-operative cultures) (NEG,
n537, 69%). The culture results from the POS and PostI-UTI cohorts are
indicated in Table 2 and represent the ‘‘uropathogen (s)’’ grown under standard
conditions. For this study, we defined a DOS urine culture as a culture with at
least 1,000 bacterial colonies forming units per milliliter reported (CFU/ml), and
included UTI symptoms (e.g. urinary burning, pain, urgency) and/or microscopic
blood in the urine as a positive UTI. The members of each cohort were similar in
demographic and clinical characteristics, including race, age, body mass index
(BMI), and incidence of diabetes, hypertension, coronary artery disease, and
smoking (S1 Table). They were also similar with respect to estrogen status, with
participants defined as estrogen-positive if they were either pre-menopausal or
were taking any source of exogenous hormones, and estrogen-negative if they
were post-menopausal and not on hormones. Participants with a positive urine
culture at any point in the 6-week peri-operative period (i.e., the DOS and PostI-
UTI cohorts) were more likely to experience post-operative UTI symptoms
relative to participants with negative urine cultures (NEG cohort) (62% and 50%
versus 22%, p50.024). On the basis of validated symptoms scales, participants in
the three cohorts reported similar bother from urinary (UDI) and colorectal
Urinary Microbiota and AMPs Indicate UTI Risk
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(CRADI) symptoms, but differed significantly in prolapse bother (POPDI,
p50.005).
Distinct Bacterial Taxa Cluster on the Basis of UTI Cohort
To identify the microbiota in each DOS urine sample, we performed PCR to
amplify the V1-V3 hypervariable regions of the 16S rRNA gene and amplicon
sequencing on the Roche 454 Titanium platform. From the 48 specimens that did
amplify, we obtained 107,532 high-quality bacterial 16S sequences for subsequent
analysis: 19,356 from the DOS POS, 5,028 from the PostI-UTI, and 83,148 from
the NEG cohorts. We were unable to amplify bacterial 16S sequences from 6 out
of 54 specimens. Taxonomy of the high-quality sequence reads was assigned using
RDP classifier v2.4 using the default 80% confidence threshold. Taxa in 204
genera, 105 families, 44 orders, 29 classes, and 18 phyla were identified (Fig. 1). In
all 3 cohorts, some participants had a urinary microbiota that was dominated by a
single taxon, representing 80–100% of all assigned reads. For example, POS cohort
specimens 868 and 1201 were 99% Staphylococcus, a member of the order
Bacillales (Fig. 2 and data not shown). POS specimens 1092 and 1173 were 99%
Klebsiella and Escherichia, both members of the order Enterobacteriales. POS
specimen 1055 was 99% Lactobacillus, while PostI-UTI specimen 1213 was 89%
Lactobacillus, a member of the order Lactobacillales. This was also true for some
NEG specimens. Specimens 787, 841 and 853 were 88–97% Lactobacillus. NEG
specimen 876 was 100% Ureaplasma of the order Mycoplasmatales, while NEG
specimen 907 was 100% Veillonella of the order Selenomonadales. However, most
microbiotas were more complex, containing several genera that comprised at least
5% of the reads [for example, specimens 892 and 916]. Yet, the most complex
bacterial community contained only eleven genera that comprised at least 1% of
Table 1. Comparison of Pelvic Floor Characteristics Based on Culture Status.
Cohort
Clinical Factors
Positive DOS culture (POS)
N513
Negative DOS culture, positive
post-operative culture (PostI-UTI)
N54
Negative DOS culture (NEG)
N537 p-value
Type of Surgery POP only 511 (85%) UI only
50 POP/UI 52 (15%)
POP only 51 (25%) UI only 51 (25%)
POP/UI 52 (50%)
POP only 516 (43%) UI only 511
(30%) POP/UI 510 (27%)
0.06
Pre-operative Urinary Distress
(UDI) Score
121 109 109 0.83
Pre-operative Prolapse Distress
(POPDI) Score
184 111 108 0.005
Pre-operative Colorectal Anal
Distress (CRADI) Score
134 63 92 0.20
% Reported (yes vs. no) Post-
operative Urinary Symptoms
8 (62%) 2 (50%) 8 (22%) 0.024
Clinical factors were collected and analyzed between the 3 cohorts by chi-squared analysis or one-way ANOVA, as appropriate. Significance within the type
of surgery (POP, UI or POP/UI), pre-operative pelvic floor symptom scores (based on pre-operative questionnaire) or post-operative urinary symptom status
is indicated as p-value (a50.05).
doi:10.1371/journal.pone.0114185.t001
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the total reads. Diversity at the family level, as measured by several tests (Shannon,
p50.003; Simpson, p50.009; Chao1, p59.161025) correlated inversely with both
a positive DOS urine culture (POS cohort) and development of a post-operative
UTI (which includes all members of the PostI-UTI cohort (4/4) and many
members of the POS cohort (6/13)). These relationships also were observed at the
order, class and phylum levels (data not shown). In contrast, there were no
correlations at any taxonomic level between diversity and any other clinical
assessment or patient demographic (data not shown).
To assess the relationship between specific bacteria and patient cohort, we
analyzed genera abundance. For example, Lactobacillus was highly abundant in all
3 cohorts on average, ranging from 16–29% of total 16S rRNA reads in each
cohort, but no statistical differences were observed between the cohorts (Table 3).
In contrast, other abundant genera (.0.5% of total reads in at least one cohort)
were found in significantly larger amounts in one cohort relative to another.
Table 2. Culture results from POS and PostI-UTI cohorts.
Specimen
Number Cohort Urine Culture Organism CFU/ml
UTI Symptoms
(per patient)
Microscopic blood
in urine
690 POS E. coli .100,000 No No
868 POS S. aureus Corynebacterium
spp.
10,000 5000 No No
916 POS P. aeruginosa 20,000 No No
1015 POS P. aeruginosa 50,000 No No
1018 POS E. coli 50,000 No No
817 POS E. coli .100,000 Yes Yes
1049 POS K. oxytoca E. coli .100,000.100,000 Yes Yes
1055 POS P. aeruginosa P. aeruginosa
Viridans Streptococcus
Group B Streptococcus
100,000 100,000 25,000 25,000 Yes Yes
1092 POS K. pneumoniae 1,000 Yes No
1173 POS E. coli .100,000 Yes Yes
1185 POS Staphylococcus spp.
Actinomyces meyeri Proteus
mirabilis
.100,000.100,000.100,000 Yes Yes
1201 POS Staphylococcus spp. E. coli .100,000.100,000 Yes Yes
1210 POS P. aeruginosa (strain 1) P.
aeruginosa (strain 2)
Lactobacillus (strain 1)
Lactobacillus (strain 2)
.100,000 50,000 6000.100,000 Yes No
1213 PostI-UTI Lactobacillus spp. 10,000 No Yes
661 PostI-UTI Enterococcus spp. 1000 No Yes
835 PostI-UTI E. coli (strain 1) E. coli (strain
2)
.100,000 3000 Yes No
1086 PostI-UTI Group B Streptococcus 12,000 Yes Yes
Urine culture bacterial counts are represented as colony forming units per milliliter (CFU/ml). UTI symptoms indicated by patient questionnaire (burning,
urgency, irritation) or microscopic evaluation for blood. In some cases, two distinct strains of the same species were identified and are indicated as ‘‘strain 1’’
or ‘‘strain 2’’.
doi:10.1371/journal.pone.0114185.t002
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Several genera were enriched in the PostI-UTI or POS cohorts. Most notably,
Fulvimonas was highly enriched in the PostI-UTI and POS cohorts relative to the
NEG cohort (p51.13610224 and 1.23610219, respectively), while Dyella was
highly enriched in the PostI-UTI cohort relative to the NEG cohort
(p53.20610210). Fulvimonas and Dyella are members of the order
Fig. 1. Bacterial diversity correlates with the susceptibility or resistance to UTI. Phylogenetic tree comparing the bacterial diversity at the Order level
within the female urinary microbiome. The bacterial diversity was compared between the three cohorts: POS (Blue), PostI-UTI (Red) and NEG (Green).
doi:10.1371/journal.pone.0114185.g001
Urinary Microbiota and AMPs Indicate UTI Risk
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Fig. 2. Bacterial abundance and phylogenetic similarity distinguishes the three UTI cohorts. Heatmap representing urine specimens clustered
according to their phylogenetic similarities. The abundance of each bacterial Order is represented by the blue boxes, with greater abundance indicated by
darker blue squares. Y-axis: Dendogram based on phylogenetic similarities. X-axis: Order. POS (Blue), PostI-UTI (Red) and NEG (Green).
doi:10.1371/journal.pone.0114185.g002
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Xanthomonadales, which was enriched in the POS and PostI-UTI cohorts
(p55.0361029 and 8.92610216, respectively). Klebsiella was enriched in the
PostI-UTI cohort relative to the NEG and POS cohorts (p56.6561023 and
7.79610210, respectively), while Escherichia/Shigella was enriched in the POS
cohort relative to the NEG cohort (p58.99610223). Both Klebsiella and
Escherichia/Shigella are members of the order Enterobacteriales, which was
enriched in the POS cohort (p52.8461024). Pseudomonas (order
Pseudomonadales) also was more abundant in the POS cohort relative to the NEG
and PostI-UTI cohorts (p59.33610219 and 2.9361024, respectively), while
Actinobaculum (order Actinomycetales) was enriched in the POS cohort relative
to the NEG cohort (p59.861023).
Other relatively abundant genera were enriched in the NEG cohort relative to
either the PostI-UTI or POS cohorts. These include members of the orders
Actinomycetales (Corynebacterium, Mobiluncus and Propionibacteria),
Clostridiales (Anaerococcus and Peptoniphilus), and Lactobacilliales (Aeroccocus,
Table 3. Wilcox analysis between Genus and Cohort.
Genus NEG vs PostI-UTI NEG vs POS PostI-UTI vs POS
p value Enriched Cohort p value Enriched Cohort p value
Enriched
Cohort
Aerococcus 4.35610206 NEG 4.79610202 PostI-UTI
Actinobaculum 9.80610203 POS
Anaerococcus 6.86610203 NEG 1.94610204 NEG
Corynebacterium 1.35610206 NEG 2.10610212 NEG
Curvibacter 4.36610206 NEG 7.40610207 NEG
Dialister 2.55610204 NEG 2.58610203 NEG
Dyella 3.20610210 PostI-UTI
Escherichia/Shigella 8.99610223 POS 1.58610208 POS
Facklamia 7.95610203 NEG 1.25610207 POS
Fastidiosipila 7.71610205 POS
Flavobacterium 2.46610204 NEG 1.62610206 NEG
Fulvimonas 1.13610224 PostI-UTI 1.23610219 POS 9.17610203 PostI-UTI
Gemella 8.01610209 NEG 5.77610213 NEG
Halomonas 3.88610207 NEG 8.70610213 NEG
Klebsiella 6.65610203 PostI-UTI 7.79610210 PostI-UTI
Lactobacillus 0.115875 PostI-UTI 0.096113 POS 0.614625 POS
Mobiluncus 1.10610204 NEG 1.91610207 NEG
Peptoniphilus 8.81610203 NEG 3.92610203 NEG
Propionibacterium 1.95610204 NEG 1.64610208 NEG
Pseudomonas 9.33610219 POS 2.93610204 POS
Streptococcus 7.52610206 NEG 4.85610211 NEG
Ureaplasma 4.82610205 NEG 2.78610208 NEG
For each of the three analyses, all statistically significant correlations are indicated as p value. Non-significant relationships are left blank. The cohort
containing a greater abundance of each genus is indicated as Enriched Cohort. None of the Lactobacillus relationships were significant.
doi:10.1371/journal.pone.0114185.t003
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Facklamia and Streptococcus), which also include Curvibacter (order
Burkholderales), Dialister (Selemonadales), Flavobacterium (Flavobacteriales),
Gemella (Bacillales), Halomonas (Oceanospirillales), and Ureaplasma
(Mycoplasmatales). Some genera were enriched in the POS cohort relative to the
PostI-UTI cohort (Escherichia/Shigella, Facklamia, Fastidosipila and
Pseudomonas), whereas others were enriched in the PostI-UTI cohort
(Aerococcocus, Fulvimonas, and Klebsiella). Pseudomonas, Escherichia and Klebsiella
were also grown using conventional urine culture (Table 2), indicating that we
can recover some genera identified from both sequencing and conventional
culture-based methods. The tendency for some genera to be associated with one
cohort over another suggests the possibility that some members of the urinary
microbiota could contribute to lower urinary tract infections, while others could
be protective.
The Distribution of Urinary AMP Levels Differs between Cohorts,
while HBD1 Levels in the NEG Cohort Correlates with Pelvic Floor
Symptom Severity
One potential reason for UTI susceptibility is differential urinary AMP
concentration and/or activity. To determine whether urinary AMPs differed
between the cohorts, we used ELISA to measure the protein levels of several
candidates (HBD1, HBD2, psoriasin and lactoferrin), which we normalized to
total urinary protein (Fig. 3). HBD1 levels were significantly lower in the POS
cohort relative to the PostI-UTI cohort (p,0.05 for POS vs. PostI-UTI) (Fig. 3A),
whereas HBD2 levels did not significantly vary between the three cohorts (one-
way ANOVA and Dunn’s Multiple Comparison test, p.0.05) (Fig. 3B). Psoriasin
levels were significantly elevated in both the POS and PostI-UTI cohorts relative
to the NEG cohort (p,0.001 for POS vs. NEG; p,0.01 for PostI-UTI vs. NEG) (
Fig. 3C), while lactoferrin was elevated in the POS cohort relative to both the
PostI-UTI and NEG cohorts (p,0.01 for POS vs. PostI-UTI; p,0.001 for POS vs.
NEG) (Fig. 3D). Together, these data demonstrate that POS urine specimens
exhibit low HBD1 levels, but high psoriasin and lactoferrrin levels compared to
the other cohorts; PostI-UTI urine specimens exhibit high HBD1 and psoriasin
levels, but low lactoferrin levels; NEG urine specimens exhibit low psoriasin and
lactoferrin levels. This suggests that differences in urinary AMP levels may indicate
UTI risk in POP/UI subjects, which may be further influenced by POP/UI status
and/or pelvic floor symptoms (Table 1).
We next determined if the levels of urinary protein or urinary AMPs might be
associated with common pelvic floor symptoms. For this analysis, we computed
Spearman’s rank correlation between urinary protein or AMP levels and pelvic
floor symptom bother. The only significant correlation between symptom severity
and urinary protein or AMP levels was identified in the NEG cohort, wherein
HBD1 levels positively correlated with prolapse bother (POPDI, Spearman’s rank
correlation +0.80; p50.01). We then determined that participants experiencing
only POP symptoms (not UI alone nor POP/UI) exhibited significantly lower
Urinary Microbiota and AMPs Indicate UTI Risk
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urinary HBD1 protein levels in the POS cohort, as compared to participants in the
NEG cohort (Mann-Whitney U test, p,0.05, data not shown). Importantly,
standard clinical microbiology protocol cultured Gram-negative bacteria from
76% (13 out of 17) of the urines from the POS and PostI-UTI cohorts (Table 2).
More specifically, 100% (11/11) of POS or PostI-UTI cohort members with only
POP symptoms grew Gram-negative bacteria as the single or predominant species.
No significant correlations were observed relative to other pelvic floor symptoms,
AMPs, or cohort (p.0.05). Collectively, these data demonstrate clear associations
between urinary HBD1 levels, the susceptibility to post-operative UTI, POP/UI
symptoms, and standard urine cultures that grew Gram-negative bacteria.
AMP Hydrophobicity, AMP Activity and Urinary Protease Activity
Cluster by Cohort
Local abundance is only one important factor that determines effectiveness of an
AMP. Other factors include peptide charge and degree of hydrophobicity, which
dictate an AMP’s ability to efficiently kill microbes and stimulate later immune
responses [34]. To link AMP hydrophobicity with the degree of AMP activity, we
Fig. 3. Urinary AMP protein levels in each UTI cohort. Urinary AMP levels were determined by ELISA and normalized to total urinary protein. A. human b-
defensin-1 (HBD1) normalized to total protein. B. human b-defensin-2 (HBD2) normalized to total protein. C. Psoriasin normalized to total protein. D.
Lactoferrin normalized to total protein. *p,0.05; **p,0.01; ***p,0.001 by One-way ANOVA and Dunn’s post-test. Median with interquartile range is shown
for each AMP.
doi:10.1371/journal.pone.0114185.g003
Urinary Microbiota and AMPs Indicate UTI Risk
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next assessed the functional capacity and hydrophobic characteristics of urinary
AMPs. High Pressure Liquid Chromatography (HPLC) was used to partially
purify urine specimens prior to analysis of antimicrobial action, which included
additional samples collected originally for AMP analyses only. The analyzed
specimens included 85% (11/13) of the POS samples, 100% (4/4) of the PostI-UTI
and 3% (1/37) of the NEG samples listed in Table 1. We also acquired additional
specimens for the AMP HPLC analyses, but were limited to AMP analyses only
due to limited specimen volume, for a total of 17 POS, 9 PostI-UTI and 17 NEG
specimens for the analysis of AMP hydrophobicity and activity. Urinary peptides
eluted between 10–55% acetonitrile. Peptides exhibiting greater hydrophobicity
eluted from the column into 27 fractions at one-minute intervals with increasing
percentages of acetonitrile, which corresponds to fractions 10–35 in Fig. 4A.
Fractions from each urine specimen were subjected to a radial diffusion assay [35]
to assess their capacity to inhibit the growth of typical Gram-positive
(Staphylococcus aureus or Group B Streptococcus) or Gram-negative (Escherichia
coli and Pseudomonas aeruginosa) uropathogens. 2 major categories were
apparent: specimens that exhibited no detectable AMP in any fraction (29% (5/
17) POS, 56% (5/9) PostI-UTI and 64% (7/11) NEG) and specimens that
exhibited various degrees of AMP activity in at least one fraction (71% (12/17)
POS, 44% (4/9) PostI-UTI and 36% (4/11) NEG). On the basis of this analysis, 5
distinct clusters became apparent (Fig. 4A). Cluster 1 consisted mostly of
specimens from the NEG (50%; 3/6) and POS cohorts (33%; 2/6). These
specimens exhibited high AMP activity (.20 mm2) against at least one tester
strain, low peptide hydrophobicity and low diversity, as indicated by the
concentration of blue squares primarily in fractions 14–16. Cluster 2 was
composed strictly of POS specimens (100%; 2/2), while cluster 3 was a mix of all 3
cohorts (PostI-UTI, 50%, 2/4); POS, 25%, 1/4); and NEG, 25%, 1/4). The
specimens in these two clusters tended to have moderate AMP activity (1–
20 mm2), low diversity and moderate hydrophobicity (fractions 21–22 and 24,
respectively). Cluster 4 was composed entirely of specimens from the POS cohort
(100%, 6/6). These specimens exhibited low-to-moderate activity (0.01–20 mm2),
moderate diversity and generally greater hydrophobicity. Finally, Cluster 5 was
Fig. 4. Correlation between urinary AMP activity, hydrophobicity and protease activity. A. Heatmap representing the degree of AMP activity
represented by the blue boxes. Proteins and peptides in urine specimens from each cohort were fractionated based upon hydrophobicity. Antimicrobial
activity of HPLC-separated urine specimens was measured by a radial diffusion assay. Zones of bacterial growth inhibition were calculated and are
represented here in a heatmap such that a darker blue color indicates a larger zone of inhibition. The specimens are clustered based on the Euclidian
distances computed from the AMP activities in different HPLC fractions (Cluster 1–5 (C1-C5)). All specimens that exhibited any detectable AMP activity
against any of the 4 bacteria tested (S. aureus, GBS, E. coli or P. aeruginosa) are represented here. Fraction number is indicated on the X-axis;
hydrophobicity of fractionated peptides increases to the right as fraction number increases (indicated by the solid black arrow). Some specimens generated
AMP activity against.1 bacteria, which accounts for the duplication of some specimen numbers on the right Y-axis of the heat map. The color designation is
indicated in a key at the top of the heat map. Zone sizes ranged from 0 mm2 to 1029 mm2. POS urine showed a higher prevalence of antimicrobial activity
(12 out of 17 specimens, 71%) than NEG urine (4 out of 11 specimens, 36%) or postI-UTI urine (4 out of 9 specimens, 44%). Specimens are boxed and
labeled along the left Y-axis of the heat map (Cluster 1–5). No color indicates undetectable antimicrobial activity within that fraction. POS (Blue), PostI-UTI
(Red) and NEG (Green). Specimen number is indicated on the right Y-axis. B. When separated into 5 distinct clusters, antimicrobial activity and AMP
hydrophobicity demonstrate a positive correlation with urinary protease activity by a Spearman’s rank correlation (R50.55, p50.010). Protease activity was
measured by an Enzcheck protease assay.
doi:10.1371/journal.pone.0114185.g004
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composed mostly of POS cohort specimens (75%, 3/4). These specimens
displayed low-to-moderate activity (0.01–20 mm2) and high diversity relative to
hydrophobicity.
For clusters 1 and 2, no statistical correlations between AMP activity and
hydrophobicity were observed in any of the cohorts. However, statistical
correlations between AMP activity and hydrophobicity were identified in several
POS and PostI-UTI specimens from clusters 3–5. In cluster 3, significant
correlations between AMP activity and hydrophobicity in the PostI-UTI cohort
were identified against Gram-positive bacteria (specimen number 835, p50.04 for
GBS), which corresponded to post-operative detection of typical Gram-negative
uropathogens (2 distinct E. coli strains) by conventional culture methods
(Table 2). No significant correlations were identified in POS or NEG specimens
from cluster 3. In cluster 4, however, significant correlations between AMP
hydrophobicity and greater AMP activity against Gram-positive bacteria were
identified in several POS specimens (specimen 690 p50.032 for S. aureus,
specimen 1049, p50.003 for GBS, p50.017 for S. aureus; specimen 1081, p50.018
for both GBS and S. aureus), which also corresponded to DOS or post-operative
detection of typical Gram-negative uropathogens (e.g., E. coli and K. oxytoca) by
conventional culture methods (Table 2). For cluster 5, we identified statistical
correlations from every participant, which included 3 from the POS and 1 from
the PostI-UTI cohorts. In the POS cohort, we observed statistical correlations
between AMP hydrophobicity and greater AMP activity against Gram-positive
bacteria (specimen 817, p5561024 for GBS, p5161024 for S. aureus), which
corresponded to a DOS culture result of E. coli (Table 2). We further identified
statistical correlations against both Gram-positive and Gram-negative bacteria in
one specimen from the POS cohort (specimen 868, p51.4161028 for GBS,
p52.2161024 for S. aureus, p51.561024 for E. coli, p52.3361026 for P.
aeruginosa), which corresponded to DOS detection of Gram-positive bacteria (e.g.
S. aureus and Corynebacterium spp) (Table 2). In the PostI-UTI cohort, we also
observed a statistical correlation between AMP hydrophobicity and greater AMP
activity against Gram-positive bacteria (specimen 661, p50.023 for GBS), which
corresponded to a post-operative detection of Gram-positive bacteria (e.g.
Enterococcus spp.) (Table 2). Collectively, these data demonstrate that AMP
activity and hydrophobicity significantly differs among the NEG, POS and PostI-
UTI cohorts. However, statistical correlations between AMP activity and
hydrophobicity were only identified in clusters 3–5, which were comprised of POS
and PostI-UTI specimens. Furthermore, the frequency of DOS or post-operative
culture of Gram-positive vs. Gram-negative bacteria in the POS and PostI-UTI
cohorts increased as cluster status increased, suggesting that less AMP activity and
more diverse peptide hydrophobicity (e.g. clusters 3–5) in the urine may directly
influence UTI risk by Gram-positive or Gram-negative bacteria.
Because proteolysis is a key process in AMP activation, we postulated that an
inherent defect in urinary protease activity could result in aberrant processing of
AMPs into inactive or more inflammatory peptides. Urine specimens were further
clustered based upon their total urinary protease activity to identify correlations
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between urinary protease activity and AMP activity between the cohorts. Total
protease activity tended to be greater in the POS cohort relative to the NEG
cohort (data not shown). Pattern analysis of the data reveals that cluster 1,
comprised of mostly NEG specimens (3/6), is characterized by the lowest degree
of protease activity and AMP hydrophobicity, but greater AMP activity. Cluster 2
consists exclusively of POS specimens (2/2), and is characterized by minimal
protease activity compared to the other clusters, but greater hydrophobicity
relative to cluster 1. Cluster 3 consists mostly of POS and PostI-UTI specimens (3/
4), and is characterized by greater protease activity and hydrophobicity relative to
clusters 1 and 2, but reduced AMP activity across the fractions. Cluster 4 also
consists exclusively of POS urines (6/6), but is characterized by greater protease
activity and peptide hydrophobicity, as well as less AMP activity across the
fractions relative to clusters 1–3. Cluster 5 consists mostly of POS specimens (3/4),
but exhibits the greatest protease activity and diversity of peptide hydrophobicity,
which corresponds to less overall AMP activity across all fractions relative to the
other clusters. When the clusters from Fig. 4A were statistically analyzed to
compare the respective protease activity (Fig. 4B), the results indicated that
cluster 5 exhibited the greatest protease activity (cluster 5: mean
42083.63¡27061.81 units) compared to clusters 1–4 (cluster 1:
17815.38¡6942.91 units, cluster 2: 13707.50¡475.18 units, cluster 3:
23433.88¡7391.06 units, cluster 4: 27921.00¡11705.70 units). Further statistical
analysis identified a significant positive correlation between cluster number and
the degree of protease activity by Spearman’s rank correlation (R50.55, p50.010).
Importantly, this increase in protease activity in cluster 5 parallels the varying
degree of peptide hydrophobicity observed in the AMP activity heat map
(Fig. 4A).
Negative correlations were also observed between urinary protease activity and
AMP activity in fractions 15 (Spearman’s rank correlation: 20.353, p50.016) and
16 (Spearman’s rank correlation: 20.333, p50.024), which corresponds with
cluster 1 comprised of mostly NEG urine specimens. In contrast, positive
correlations were identified in fractions 27 (Spearman’s rank correlation: 0.565,
p54.2461025), 30 (Spearman’s rank correlation: 0.482, p56.861024), 31
(Spearman’s rank correlation: 0.563, p54.6361025) and 32 (Spearman’s rank
correlation: 526, p51.861024), which consisted of 90% POS specimens.
Collectively, these data indicate that the degree of protease activity can dictate the
degree of AMP hydrophobicity, and thus activity, in a given urine specimen,
which may serve as a mechanism for increased risk for UTI in the POS and PostI-
UTI cohorts
Discussion
Numerous studies of the impact of microbiota on non-urothelial tissues have
established dynamic and vital interactions between resident microbiota and host
physiology or pathology [10, 12, 19, 36, 37]. Emerging evidence reveals that
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invading pathogens must compete with the endogenous microbiota, while
simultaneously evading host innate immune responses. Given the existence of the
newly discovered female urinary microbiota [13, 14, 19, 38], the same is likely true
of pathogens implicated in post-operative UTIs. Therefore, pathogenesis of the
female lower urinary tract would involve a series of complex and interdependent
communications between the host and her urinary microbiota that are not well
understood.
The current study links POP symptoms and POP/UI surgery with a positive
urine culture on the day of surgery and reveals significant differences in the DOS
urinary microbiota of women who developed a post-operative UTI (POS and
PostI-UTI cohorts) relative to those who did not develop UTI. For this study, we
defined a DOS urine culture as a culture with at least 1,000 bacterial colonies
forming units per milliliter reported (CFU/ml), along with UTI symptoms and/or
microscopic blood in the urine (Table 2). This differs from most other studies in
that 10,000 CFU/ml is typically considered a UTI, despite the presence or absence
of urinary symptoms (e.g. burning, urgency, pain, blood). False-negative UTI
results put patients at-risk for developing secondary complications, such as
urinary biofilm formation, pyelonephritis and/or pelvic floor pain and
dysfunction. In parallel, using a CFU/ml of 10,000 would not allow for clinicians
to distinguish between a true UTI and asymptomatic bacteriuria, which may
promote the use of unnecessary antibiotics. The urinary bacteria detected by 16S
rRNA sequencing is not due to sample contamination, as we have thoroughly
compared the urinary microbiota in clean-catch urine, urine from transurethral
catheter, and urine from suprapubic aspirate [7, 13]. Our group has further
determined that extended urinary cultures are necessary to grow viable bacteria
from urine, as .90% of all bacteria are unculturable by current laboratory
techniques. Urine was shown to contain communities of living bacteria that
comprise a resident female urine microbiota, which parallel the predominant
bacteria detected by 16S rRNA sequencing data from the same subjects [14]. Thus,
the bacteria detected in the culture-negative subjects are not due to contamina-
tion, but likely represent a ‘‘protective’’ microbiota. Further studies are necessary
to determine if intracellular bacterial communities exist in these subjects, or
whether the bacteria are planktonic in nature within the urinary tract. The
establishment of a urinary microbiome emphasizes the need to redefine ‘‘UTI’’ to
include both urinary symptoms and microbiome analyses, in addition to extended
culture results [14], as part of the clinical diagnosis of UTI.
Our prior work documented that members of the POS cohort have an
increased risk for post-operative UTI [7]. Given that the bladder environment of
women with POP is likely different from that of women without POP [7], it is not
surprising that the POS cohort was comprised entirely of women who underwent
POP surgery. Women with a diverse bladder microbiota appear to be protected
from UTI risk both pre-operatively and post-operatively relative to those with a
bladder microbiota dominated by a single genus. We propose that POP tends to
generate a niche conducive to certain bacteria that either contribute to UTI
symptoms or at least act as biomarkers for women at risk for post-operative UTI.
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These bacteria might be those that were more abundant and/or more frequent in
the POS and/or PostI-UTI cohorts. Examples at the genus level include
Escherichia/Shigella, Klebsiella, and Pseudomonas. Examples also include Dyella
and Fulvimonas, members of the family Xanthomonadaceae, which includes the
emerging Gram-negative urinary pathogen Stenotrophomonas [39, 40]. Other
examples include Aerococcus (Family: Aerococcaceae) and Actinobaculum (Family:
Actinomycetaceae), which includes the species A. urinae and A. schaalii,
respectively, two emerging Gram-positive urinary pathogens [41]. Further studies
are necessary to identify potential metabolic or environmental factors that allow
for bacterial dominance or diversity in POP/UI subjects.
This study also revealed a previously unidentified association between the
urinary levels of HBD1 and POP symptoms. Members of the NEG cohort
exhibited a positive correlation between HBD1 and POP symptom severity. The
relationship between HBD1 and POP symptom severity is intriguing, especially
given the linkage between the POS cohort, POP symptoms and surgery, and
certain bacterial taxa. These data are important from a clinical perspective, as this
indicates that individuals in the NEG cohort who exhibit POP symptoms are
likely to have higher urinary levels of HBD1, as compared to individuals with POP
symptoms in the POS or PostI-UTI cohort. Furthermore, this suggests that
participants in the POS or PostI-UTI cohort experiencing POP symptoms alone
may be more likely to develop a Gram-negative UTI, as Gram-negative bacteria
were cultured from 92% of subjects with POP alone in these 2 cohorts. Women
with significant anatomical distortion due to POP may have altered AMP profiles
or characteristics; for example, it may be that HBD1 is protective for women with
POP. Therefore, individuals who exhibit POP symptoms and exhibit lower levels
of urinary HBD1 would, presumably, be at a greater risk for UTI. Female urine
contains two predominant HBD1 bands that are more abundant in pregnant
females [21], suggesting that the hormonal milieu (i.e. pregnancy, pre- or post-
menopausal) likely influences urinary AMP regulation. We speculate that HBD1
may serve to encourage bacterial tolerance in the urinary tract and discourage the
overgrowth of pathogenic or opportunistic microbes under normal conditions.
However, subjects in the POS or PostI-UTI cohorts with POP symptoms alone
likely exhibit unknown mechanisms that reduce the production of urinary HBD1
and render them more susceptible to post-operative UTI.
Although psoriasin levels were higher in both the POS and PostI-UTI cohorts
relative to the NEG cohort, E. coli was the most common uropathogen routinely
cultured from the urine of participants from the POS and PostI-UTI cohorts.
Psoriasin is a calcium-binding protein that normally exhibits potent antimicrobial
activity against several strains of E. coli by sequestering of Zn2+ [32, 42], and has
been suggested as a urinary biomarker for bladder squamous cell carcinoma [43].
The observed increase in urinary psoriasin levels in the POS and PostI-UTI
cohorts indicates that the activity of urinary psoriasin against E. coli may be
compromised in these 2 cohorts, which could be due to defects in the urinary
ionic environment or bladder squamous cell activity, all of which require further
exploration.
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The observation that the POS cohort exhibited significantly higher lactoferrin
levels compared to the NEG and PostI-UTI cohorts could indicate that some
members of the POS cohort may be in the initial stages of a UTI on the DOS, as
leukocyte-derived lactoferrin has been found to be a biomarker of UTI [31].
Unlike HBD1, HBD2 and psoriasin, native lactoferrin exerts its antimicrobial
action through sequestration of iron [31]. This suggests that elevated lactoferrin in
the POS cohort may serve as a compensatory mechanism to block iron acquisition
by specific urinary bacteria, particularly E. coli, which require iron for survival or
virulence and exhibit highly effective scavenging mechanisms for iron acquisition
[44]. Alternatively, the elevated levels of urinary lactoferrin in the POS cohort may
facilitate the colonization or proliferation of pathogens that rely less on iron
availability, or interfere with commensals and beneficial bacteria that require iron
for survival. Studies are currently underway to identify potential mechanisms by
which the metabolic responses of the urinary microbiome are disrupted in POP/
UI subjects.
Although other studies in mice and humans detected cathelicidin in the urine
[25, 45], we were unable to detect cathelicidin in urine samples from our
participants. We speculate that, due to the nature of our patient population, POP/
UI patients might express lower levels of urinary cathelicidin compared to other
subsets of UTI-susceptible populations; this speculation warrants further
investigation. Furthermore, the ability of AMPs function indirectly as signaling
molecules to stimulate chemokine production, modulate dendritic and/or T cell
function, promote chemotactic activity and regulate Toll-Like Receptor (TLR)
pathways indicates alternative mechanisms by which altered urinary AMP levels
may be increasing the risk for PostI-UTI, and is currently being investigated [46–
48]. Of note, RNAase 7 is currently the most abundant AMP in the urinary tract,
specifically in the urothelium of the bladder, ureter, and kidney, and also exhibits
potent antimicrobial properties against both Gram-negative and Gram-positive
uropathogens [23, 24]. Thus, RNAse 7 expression or activity may also play a key
role maintaining a protective urinary microbiota, and should be evaluated in this
patient population.
Statistical analyses of urinary AMP and protease activity identified distinct
differences between the cohorts that paralleled the degree of urinary peptide
hydrophobicity, where greater protease activity and diversity of peptide
hydrophobicity was observed exclusively in the POS and PostI-UTI cohorts
compared to the NEG cohort. Hydrophobicity and amphipathicity are considered
two critical factors for AMPs that target microbial membranes. Further increases
in peptide hydrophobicity were found to dramatically reduce overall AMP activity
by promoting peptide dimerization in alpha-helical peptides [49]. One
mechanism for aberrant peptide hydrophobicity could be an inherent defect in
host protease activity, since proteolysis is a key process in AMP activation [50]-
[54]. The enhanced urinary proteolyic activity observed in the POS and PostI-UTI
cohorts may result in more hydrophobic inactive peptides that permit the
colonization and growth of specific bacteria that were found to be more abundant
in these cohorts relative to the NEG cohort. Epithelial protease activity is
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necessary to activate mature AMP proteins and is highly dependent upon the pH
[55], yet we did not observe any statistical correlations between urinary pH and
protease activity. Host protease production and/or may be enhanced by the
urothelium or by infiltrating immune cells in response to the bladder microbiota.
Alternatively, bacterial protease activity derived directly from the bladder
microbiota could alter host AMP activity, likely as a selective advantage to allow
for colonization and/or proliferation of known or emerging uropathogens. For
example, proteases derived from a pathogenic strain of Porphyromonas gingivalis
were found to degrade HBD3 in a dose- and time-dependent fashion in vitro [56].
Notably, exposure of HBD3 to culture supernatants derived from P. gingivalis
diminished HBD3-mediated AMP activity against S. aureus, while the presence of
specific protease inhibitors increased the antimicrobial efficacy of HBD3 against P.
gingivalis in identical assays. These data highlight the fact that the antimicrobial
capacity of urinary AMPs (host or bacterial) and urinary protease activity directly
factors into the susceptibility of POP/UI subjects to UTI.
Together, our data suggest that the urinary microbiota composition (i.e.,
frequency and/or abundance) and AMP profile (i.e., distribution, activity and/or
hydrophobicity) in DOS urine could serve as biomarkers in the future to facilitate
the identification of women at risk for post-operative UTI. Although we cannot
generalize this finding to other clinical populations, it is unlikely that this
population is biologically unique with regard to UTI risk. Although the
importance of the urinary microbiota under physiologic or pathologic conditions
is largely unexplored, our data now demonstrate an interdependence between
specific urinary microbiota and host urinary AMPs with direct implications for
UTI susceptibility and POP symptoms in POP/UI subjects. AMPs act both as
modulators of microbial colonization and coordinators of host inflammatory
processes, and AMPs have been associated with symptom severity in other
inflammatory diseases and infection [36, 52, 57]. Thus, the spectrum and
abundance of AMPs (host versus bacterial) in the urine likely contributes to both
UTI susceptibility and UTI-symptoms (e.g., burning and irritation) by directly
influencing the development of microbial communities in the bladder. Although
we cannot distinguish between urothelial, immune cell or bacterial-derived AMPs
in the urine specimens used in the present study, ongoing work aims to identify
the various AMPs present in urine specimens from the three cohorts.
Further insight into the mechanisms by which bladder microbiota and host
AMPs communicate during homeostasis and pathologic states will be critical to
our understanding of the pathogen-host interactions in the bladder, and facilitate
the development of better prevention and/or treatment strategies for UTI in POP/
UI subjects and other UTI-susceptible populations. Unfortunately, the clinical
criteria for UTI are not well defined. Furthermore, there is no universally
accepted, clinically relevant UTI definition that is useful for human research
purposes. Commonly, UTI definitions are multi-faceted, requiring symptoms
such as urgency, frequency, urinary incontinence, or dysuria and a positive urine
culture by standard clinical microbiology methods. Yet, patients often experience
‘‘UTI symptoms’’ (i.e., burning, urgency, irritation) despite a negative urine
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culture, using traditional laboratory procedures and thresholds. This discordance
between symptoms and culture status results in diagnostic uncertainty and further
contributes to the economic burden associated with UTIs [58, 59].
Experimental Procedures
Patient Population and Urine Collection
All Human Participants procedures were reviewed and approved by the Loyola
University Chicago Institutional Review Board. We recruited a cohort of
participants undergoing POP and/or UI surgery, which was a larger study
assessing the presence or absence of the female urinary microbiota [7]. Women
were excluded if they were not English speaking, unable to complete the
questionnaires, were not undergoing POP/UI surgery, had recurrent UTIs, had
recent treatment for UTI or were on active antibiotic treatment for UTI. Urine
was collected via trans-urethral catheter prior to administration of one dose of
intravenous peri-operative antibiotics. All participants provided written informed
consent for research participation. Pelvic floor symptoms can be measured using
the validated pelvic floor distress inventory questionnaire (PFDI), which has 3
subscales that detect symptom presence and quantify symptom bother from
urinary (urinary distress inventory (UDI)), prolapse (pelvic organ prolapse
distress inventory (POPDI)) and colorectal anal symptoms (colorectal anal
distress inventory (CRADI)) [60, 61].
Urine Culture Methods
Routine microbial urine culture consisted of inoculation of sheep blood agar and
MacConkey agar plates with 1 microliter of urine and examination of plates for
bacterial growth after 24 hours incubation at 35 C˚ in room atmosphere. For this
study, we defined a DOS urine culture as a culture with at least 1,000 bacterial
colonies forming units per milliliter reported (CFU/ml), along with UTI
symptoms and/or microscopic blood in the urine (Table 2). To determine the
protein detection method most appropriate for protein normalization in urine, we
measured several specimens using three different assays: a Bradford assay, a
modified Lowry assay, and a bicinchoninic acid (BCA) assay. Protein levels from
the three protein assays were compared with protein levels determined by an
automated system (Beckman Coulter DXC, Pasadena, CA) in the Loyola
University Chicago Health Sciences Campus clinical laboratory. We concluded
that the Bradford assay was the most accurate method to measure urinary protein
for the studies.
Pelvic Floor Distress Inventory (PFDI) and UTI Cohorts
All participants completed the long form of the PFDI prior to surgery. During the
6 week post-operative period women were queried on their urinary symptoms at
their post-operative visits and a catheterized urine culture specimen was collected
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from any participants with signs or symptoms consistent with a UTI (i.e. positive
urine dipstick, dysuria, frequency, urgency). Post-operative UTI was defined as a
urine culture with at least 1,000 bacterial colonies per milliliter. Participants were
divided into cohorts based on urine culture status. The three cohorts were those
with positive DOS urine cultures, those with negative DOS cultures who
developed post-operative UTI, and those with negative urine cultures throughout
the 6-week post-operative period.
Microbial DNA Isolation
Within 4 h of collection, the urine specimens were centrifuged at 50006g for
10 min and the resulting pellets were re-suspended in DNA stabilization buffer
[62]. Swabs were washed with sterile phosphate buffered saline supplemented with
DNA stabilization buffer. All specimens were frozen at 280 C˚ until microbial
DNA isolation and sequence analysis. All genomic DNA (gDNA) isolations from
the urine specimens and from the reagent-only control specimens were performed
within a laminar flow hood. Total gDNA was isolated from urines using the
Qiagen DNeasy blood and tissue extraction kit (Qiagen) with the Gram-positive
bacteria protocol. The gDNA was stored at 4 C˚ until 16S PCR amplification.
Amplicon sequencing libraries were quantified by fluorescent Quant-It dsDNA
assay (Life Technologies).
Sequence Processing
The Mothur software (version 1.23.0) [63] was applied to deconvolute the 454
sequence reads into individual samples based on perfect match to the barcode
sequences. Primers and barcodes were trimmed from each read and the trimmed
sequences shorter than 200 bp were discarded. Low-quality and chimeric
sequences were removed with default Mothur parameters. Taxonomic classifica-
tion (from phylum to genus level) of the sequence reads was performed by the
RDP Classifier (version 2.4) [64] with the default 0.8 confidence threshold.
ELISAs and Protease Assay
AMP concentrations were measured by ELISA; human b-defensin-1 (PeproTech,
Cat # 900-K202), human b-defensin-2 (PeproTech, Cat # 900-K172), psoriasin
(Circulex, Cat # CY-8073) and lactoferrin (AssayPro, Cat # EL2011-1). Protease
activity was assessed with an Enzchek protease assay (Invitrogen, Cat # E6638).
All were conducted according to the manufacturers’ instructions.
HPLC purification of urine
Urine was subjected to peptide separation using a Shimadzu HPLC system.
Chilled specimens were passed through a C18 column (Thermo Scientific) with
acetonitrile running buffer to separate urinary peptides based on their degree of
hydrophobicity. HPLC was equilibrated in 0.1% trifluoroacetic acid at a flow rate
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of 2.0 ml/min and fractions were collected at one-minute intervals between 10–
55% acetonitrile. Peptide and protein concentration was monitored by UV
absorption at 214 and 280 nm, respectively. Respective fractions from three
separate runs of each sample were combined, lyophilized, resuspended in 10 ml of
sterile ddH20 (Life Technologies), and then vortexed for one hour at 4 C˚. We first
tested recombinant psoriasin and HBD-1 to determine the approximate elution
time for known urinary AMPs. As expected, because of their amphipathic nature,
both AMPs eluted off of the column at an intermediate concentration of
acetonitrile between 40% and 55% acetonitrile (data not shown).
Peptides and Bacteria
Peptides were purchased from Imgenex (San Diego, CA, USA) and 95% purity
was confirmed by mass spectrometry. GBS was grown in Todd Hewitt Broth
(THB). Staphylococcus aureus SA113, Staphylococcus aureus DmprF [65], and E.
coli ATCC 25922 were grown in Tryptic Soy Broth (TSB).
Antimicrobial radial diffusion assay
HPLC fractions were evaluated by radial diffusion assay, as previously described
[35, 66, 67]. Antimicrobial activity was analyzed against the microorganisms listed
above. Thin plates (1 mm) with 1% SeaKem GTG Agarose (Cambrex
Corporation, East Rutherford, NJ) in 0.5% tryptone containing ,56106 cells/ml
of bacteria were used for the assay. 1 ml water was used as a negative control and
applied to separate wells. As a positive control, 1 ml of synthetic CRAMP (64 mM)
was applied to separate wells. Plates were incubated overnight at 37 C˚. The zone of
inhibition was quantified by determining the area of bacterial clearance
surrounding the center well using Image J Software.
Statistical analysis
Clinical and demographic factors were collected and analyzed by chi-squared
analysis or one-way ANOVA, as appropriate, using SPSS version 19. AMP ELISA
data were analyzed using GraphPad Prism, version 5 (GraphPad Software, Inc.,
San Diego, CA). ELISA data were analyzed by one-way ANOVA with post-tests. P
values ,0.05 were considered significant. Microbial diversity indices were
computed from subsampled sequence data, which were performed by subsam-
pling without replacement of 1000 reads from each sample for 1000 times (if a
sample has less than 1000 reads in total, all of its reads will be used for analysis
without the subsampling step) to avoid bias caused by the different sequencing
depths of samples as previously described [68, 69]. Comparison of the bacterial
abundance between different cohorts was performed using the metagenomeSeq
package with its built-in multiple test correction [70]. All the statistical tests were
performed with customized scripts implemented with the freely available R
software environment (http://www.r-project.org). All of the sequences and
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associated metadata were deposited to the NCBI Sequence Read Archive under the
accession number SRP045483.
Supporting Information
S1 Table. Participant Demographics. The members of each cohort were similar
in demographic and clinical characteristics, including race, age, body mass index
(BMI), and incidence of diabetes, hypertension, coronary artery disease, smoking
and estrogen status.
doi:10.1371/journal.pone.0114185.s001 (DOC)
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